Aeneas Capital and Pyrinas Target Launch of US$120m Fund to Develop Co-Working Laboratory Ecosystems for Life Sciences Start-Ups in the United States

HONG KONG–(BUSINESS WIRE)–May. 16, 2019 Aeneas Capital and Pyrinas, both affiliated companies to Aptorum Group Ltd (Nasdaq: APM), is launching its flagship fund – Pyrinas US Healthcare Real Estate Fund 1 SP – to acquire and develop co-working space and incubator facilities for the life sciences sector in the United States; Opportunity to invest in […]

Q3 Medical Devices Limited Enters into a Distribution Agreement with Medtronic for its Biodegradable Biliary and Pancreatic Stent

DUBLIN–(BUSINESS WIRE)–May. 15, 2019 Q3 Medical Devices Limited (“Q3 Medical”) based in Dublin, Ireland, announced today that it has entered into a distribution agreement with Medtronic plc for ARCHIMEDES, the first to market fully biodegradable biliary and pancreatic stent designed as an alternative to traditional plastic stents. Medtronic’s Gastrointestinal and Hepatology business, which is part […]

Takeda Simplifies Portfolio and Accelerates Deleveraging Through Two Divestitures

Agrees to Sell Xiidra® to Novartis for up to $5.3 billion Company to Also Divest TachoSil® to Ethicon* for approximately $400 million OSAKA, Japan–(BUSINESS WIRE)–May. 08, 2019 Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into agreements to divest its Xiidra® (lifitegrast ophthalmic solution) 5% product (“Xiidra®”) to Novartis and its TachoSil® Fibrin […]

Aptorum Group Establishes Smart Pharma to Focus on Computational Repurposed Drug Discovery for Orphan and Unmet Diseases

SINGAPORE–(BUSINESS WIRE)–Apr. 24, 2019 Aptorum Group Limited (Nasdaq: APM) today announced the establishment of a new subsidiary group, Smart Pharma (“SmartP”), which operates its novel computational repurposed drug discovery, modeling and validation platform, together referred to as the “Smart-ACTTM” platform. Smart-ACTTM stands for Accelerated Commercialization of Therapeutics and encompasses state-of-the-art technology in systematic screening of […]

Terns Pharmaceuticals to Present Preclinical Data on Two Lead Programs at the European Association for the Study of the Liver (EASL) Annual Meeting 2019

TERN-101 Demonstrated Potency as an Agonist of FXR Nuclear Hormone Receptor TERN-201 Demonstrated Potency as an Inhibitor of SSAO (VAP-1) SAN MATEO, Calif. & SHANGHAI–(BUSINESS WIRE)–Apr. 01, 2019 Terns Pharmaceuticals, Inc. today announced presentation of preclinical data on its two lead programs at The International Liver Congress™ 2019, the Annual Meeting of the European Association […]

Terns Pharmaceuticals Announces the Appointment of Erin Quirk M.D. as Chief Medical Officer

SAN MATEO, Calif. & SHANGHAI–(BUSINESS WIRE)–Jan. 17, 2019 Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing molecularly targeted, oral, small-molecule drugs to treat NASH and cancer, announced today the appointment of Erin Quirk, M.D. as Chief Medical Officer (CMO). Dr. Quirk brings more than two decades of clinical medicine and drug […]

Terns Pharmaceuticals Completes $80 Million Series B Financing to Advance Pipeline of Drugs to Treat NASH and Cancer

Proceeds to Support Development of Clinical and Preclinical NASH Candidates Financing Led by Vivo Capital and OrbiMed, joined by Decheng Capital Lilly Asia Ventures, the Series A investor, also investing in the Series B round SAN MATEO, Calif. & SHANGHAI–(BUSINESS WIRE)–Oct. 30, 2018 Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing […]

Mitsui Chemicals and Chitose Group Launch Novel Open Innovation Initiative to Foster Businesses and Talents

Bringing Together Unique Technologies for Joint Commercialization TOKYO–(BUSINESS WIRE)–Oct. 29, 2018 Mitsui Chemicals, Inc. (TOKYO:4183)(President & CEO: Tsutomu Tannowa) and Chitose Group (CEO: Tomohiro Fujita), a group of biotechnology startups, have jointly launched the "0 to 1 Project" as a novel open innovation initiative to foster "business and talents” based on unique technology seeds. In […]

AMPLEXOR Life Sciences Attending Annual Pharmacon Asia 2018

–(BUSINESS WIRE)–Sep. 17, 2018 AMPLEXOR: MEDIA ADVISORY: Now in its fifth year, Pharmacon Asia 2018 is one of the industry’s most highly regarded drug development and commercialization value chain events that focuses on clinical trials to market access, and addresses challenges relating to maintaining regulatory compliance. Pharmacon Asia is known for its speaker line-up and […]

JAMA Publishes Greatly Anticipated Phase III Study Using 22nd Century’s SPECTRUM® Very Low Nicotine Content Cigarettes

Immediate reduction in nicotine content is the clear winner WILLIAMSVILLE, N.Y.–(BUSINESS WIRE)–Sep. 05, 2018 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction and Very Low Nicotine tobacco, announced today that the Journal of the American Medical Association (JAMA) published results of a greatly anticipated independent clinical study […]

Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase I II ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia

Results showed a significant reduction in transfusion burden compared to placebo Safety profile generally consistent with previously reported data Regulatory submissions planned in the United States and Europe in the first half of 2019 SUMMIT, N.J. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jul. 09, 2018 Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results […]